Quality by Design tools such as design of experiments (DOE) help to provide a more thorough understanding of a product's design
space. Excipient robustness studies using DOE are, thus, used to evaluate and characterize the formulation design space. The
formulation design space is identified by the ranges established during the excipient robustness study to provide an assurance
of quality in the product. Controls included in manufacturing batch records and product specifications ensure that the product
is maintained within the formulation design space so that the quality of the product and safety of the patient are ensured.
At the time of the article's writing, Adeola O. Grillo, PhD, was a senior scientist in the department of drug product sciences, biopharmaceutical development, Human Genome Sciences,
Rockville, MD. She is currently an assistant professor in the department of pharmaceutical sciences at the Feik School of
Pharmacy, University of the Incarnate Word, San Antonio, TX, 210.883.1099, firstname.lastname@example.org
Martin Kane is an associate director of process statistics in the department of biostatistics, Neçois Penn is a bioprocess associate in the department of drug product sciences, and Melissa Perkins, PhD, is the director of the department of drug product sciences, all in biopharmaceutical development at Human Genome Sciences,
Rockville, MD, email@example.com
1. US Food and Drug Administration. Guidance for industry. Pharmaceutical cGMPs for the 21st century—A risk-based approach
final report. Rockville, MD; 2004 Sept.
2. International Conference on Harmonization (ICH). Q8(R1), Pharmaceutical Development. Geneva, Switzerland; 2008 Nov.
3. ICH. Q9, Quality Risk Management. Geneva, Switzerland; 2005 Nov.
4. ICH. Q10, Pharmaceutical Quality System. Geneva, Switzerland; 2008 June.
5. Bedu-Addo F, Moreadith R, Advant SJ. Preformulation development of recombinant pegylated staphylokinase SY161 using statistical
design. AAPS PharmSci. 2002;4(4):E19.
6. Cleland JL, Lam X, Kendrick B, Yang J, Yang TH, Overcashier D, et al. A specific molar ratio of stabilizer to protein is
required for storage stability of a lyophilized monoclonal antibody. J Pharm Sci. 2001;90(3):310–21.
7. Andya JD, Maa YF, Costantino HR, Nguyen PA, Dasovich N, Sweeney TD, et al. The effect of formulation excipients on protein
stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody. Pharm Res.
8. Gupta S, Kaisheva E. Development of a multidose formulation for a humanized monoclonal antibody using experimental design
techniques. AAPS PharmSci. 2003;5(2):E8.
9. Fransson J, Hagman A. Oxidation of human insulin-like growth factor I in formulation studies, II. Effects of oxygen, visible
light, and phosphate on methionine oxidation in aqueous solution and evaluation of possible mechanisms. Pharm Res. 1996;13(10):1476–81.
10. Maltesen MJ, Bjerregaard S, Hovgaard L, Havelund S, van de Weert M. Quality by design—spray drying of insulin intended
for inhalation. Eur J Pharm Biopharm. 2008;70(3):828–38.
11. Guo C, Stine KJ, Kauffman JF, Doub WH. Assessment of the influence factors on in vitro testing of nasal sprays using Box-Behnken
experimental design. Eur J Pharm Sci. 2008;35(5):417–26.
12. Dayal P, Pillay V, Babu RJ, Singh M. Box-Behnken experimental design in the development of a nasal drug delivery system
of model drug hydroxyurea: characterization of viscosity, in vitro drug release, droplet size, and dynamic surface tension.
AAPS PharmSciTech. 2005;6(4):E573–85.
13. Zidan AS, Sammour OA, Hammad MA, Megrab NA, Habib MJ, Khan MA. Quality by design: understanding the formulation variables
of a cyclosporine. A self-nanoemulsified drug delivery systems by Box-Behnken design and desirability function. Int J Pharm.
14. Campisi B, Chicco D, Vojnovic D, Phan-Tan-Luu R. Experimental design for a pharmaceutical formulation: optimisation and
robustness. J Pharm Biomed Anal. 1998;18(1–2):57–65.
15. Gabrielsson J, Sjöström M, Lindberg NO, Pihl AC, Lundstedt T. Robustness testing of a tablet formulation using multivariate
design. Drug Dev Ind Pharm. 2006;32(3):297–307.
16. Stoner MR, Fischer N, Nixon L, Buckel S, Benke M, Austin F, Randolph TW, Kendrick BS. Protein-solute interactions affect
the outcome of ultrafiltration/diafiltration operations. J Pharm Sci. 2004;93(9):2332–42.
17. Harinarayan C, Skidmore K, Kao Y, Zydney AL, van Reis R. Small molecule clearance in ultrafiltration/diafiltration in
relation to protein interactions: Study of citrate binding to a Fab. Biotechnol Bioeng. 2009;102(6):1718–22.